Webdisclosure.com

Search

EUROPEAN HEALTHCARE ACQUISITION & GROWTH COMPANY B.V. EQS-Adhoc: European Healthcare Acquisition & Growth Company B.V.: Expiry and delisting of the Warrants on 17 November 2023

Directive transparence : information réglementée

10/11/2023 07:30

EQS-Ad-hoc: European Healthcare Acquisition & Growth Company B.V. / Key word(s): Miscellaneous
European Healthcare Acquisition & Growth Company B.V.: Expiry and delisting of the Warrants on 17 November 2023

10-Nov-2023 / 07:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


NOT FOR DISTRIBUTION, PUBLICATION OR FORWARDING, EITHER DIRECTLY OR INDIRECTLY, IN OR TO CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.

 

Public disclosure of inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)

 

European Healthcare Acquisition & Growth Company B.V. – Expiry and delisting of the Warrants on 17 November 2023

 

Munich, 10 November 2023

European Healthcare Acquisition & Growth Company B.V. (the "Company"), a Dutch operators-led special purpose acquisition company listed on Euronext Amsterdam, today announces that the class A warrants (the "Public Warrants") and the class B warrants (the "Founder Warrants" and together with the Public Warrants, the "Warrants") will expire worthless on the original business combination deadline, being 17 November 2023.

On 4 October 2023, the board of the Company proposed that in the context of the proposed extension of the business combination deadline as announced in the Company's press release of 20 September 2023 and as further set out in the agenda and explanatory notes of the EGM to be held on 15 November 2023, the holders of the Warrants amend the terms and conditions of the Warrants (the "Warrant T&C") to have all Warrants expire worthless on the original business combination deadline, being 17 November 2023, as the Warrants have proved to impede the Company's chances of successfully executing a business combination.

69% of the outstanding Warrants voted in favour of the amendment of the Warrant T&C by the expiry of the voting deadline of 9 November 2023 at 17:30 CET. The Warrant T&C provide that the terms of the Warrants may be amended with the vote or written consent of the holders of at least 50% of the then outstanding Warrants. Therefore the Warrants will expire on the original business combination deadline, being 17 November 2023.

Delisting of the Warrants shall occur on 17 November 2023 and, accordingly, the last trading day of the Warrants shall be 16 November 2023.

Following expiry of the Warrants, the share capital and Warrants of the Company are as follows:

Public Shares outstanding 1,238,962
Public Shares held in treasury 168,761,038
Class B ordinary shares outstanding 6,666,666
Redeemable class A warrants nil
Class B warrants nil

 

 

-----------

 

About EHC

EHC is an operators-led special purpose acquisition company. With its exclusive focus on healthcare, EHC is the first of its kind in Europe and benefits from excellent investment opportunities driven by the market’s underlying fundamentals and an excellent value creation potential. In addition, the sponsors have created a novel structure which materially innovates the special purpose vehicle concept to allow a very attractive alignment of interests of all stakeholders.

 

General Enquiries

+49 89 4523240

info@ehc-company.com

 

Media Enquiries

FGS Global

Kai Peter Rath

+49 211 43079 209

kai.rath@fgsglobal.com

 

Important Notice

This publication may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of European Healthcare Acquisition & Growth Company B.V. (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Securities of the Company have not been, and will not be, registered under the Securities Act. The Securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.

 

In the United Kingdom, this publication is only being distributed to and is only directed at persons who are "qualified investors" within the meaning of Article 2 of the Prospectus Regulation as it forms part of retained EU law in the United Kingdom as defined in the European Union (Withdrawal) Act 2018 (as amended) and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This publication is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this publication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

 

The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any Retail Investor in the EEA. For these purposes, a "Retail Investor" means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments, as amended ("MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97 of the European Parliament and of the Council of 20 January 2016 on insurance distribution, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014 of the European Parliament and of the Council of 26 November 2014 on key information documents for packaged retail and insurance-based investment products (the "PRIIPs Regulation") for offering or selling the Securities or otherwise making them available to Retail Investors in the EEA has been prepared and therefore offering or selling the Securities or otherwise making them available to any Retail Investor in the EEA may be unlawful under the PRIIPs Regulation.

 

Solely for the purpose of the product governance requirements contained within MiFID II, (ii) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 of 7 April 2016 supplementing MiFID II and (iii) local implementing measures (together, the "MiFID II Requirements"), and disclaiming any and all liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Requirements) may otherwise have with respect thereto, the Public Shares and Public Warrants have been subject to a product approval process. As a result, it has been determined that (i) the Public Shares are (a) compatible with an end target market of Retail Investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II, and (b) eligible for distribution through all distribution channels permitted by MiFID II and (ii) the Public Warrants are (a) compatible with an end target market of investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II, and (b) eligible for distribution to professional clients and eligible counterparties through all distribution channels permitted by MiFID II.

 

This release may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release. We undertake no obligation, and do not expect to publicly update, or publicly revise, any of the information, forward-looking statements or the conclusions contained herein or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof, whether as a result of new information, future events or otherwise. We accept no liability whatsoever in respect of the achievement of such forward-looking statements and assumptions.

 

To the extent permissible under applicable law or regulation, and in accordance with Dutch market practice, the Company or its brokers may purchase, or conclude agreements to purchase, shares in the Company, directly or indirectly, outside of the scope of the redemption offer, before, during or after the period in which the redemption offer remains open for acceptance. This also applies to other securities that are directly convertible into, exchangeable for, or exercisable for shares in the Company. These purchases may be completed via the stock exchange at market prices or outside the stock exchange in negotiated transactions. Any information about such purchases will be disclosed as required by law or regulation in the Netherlands or any other relevant jurisdiction.

 

 



End of Inside Information

10-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: European Healthcare Acquisition & Growth Company B.V.
c/o ALR Treuhand GmbH; Theresienhöhe 28
80339 München
Germany
ISIN: NL0015000K10, NL0015000K28
WKN: A3C60V
Listed: Regulated Unofficial Market in Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1770087

 
End of Announcement EQS News Service

1770087  10-Nov-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1770087&application_name=news&site_id=symex